Generics Industry Preps For Potential Entry Of Ukraine Into EU

Generics Industry Has Provided Substantial Support Since Russian Invasion

 
• By Chloe Kent
  
Generate a summary of this article
Listen to this article
Beta

Generics industry trade group Medicines for Europe has met with Ukrainian government officials to discuss how to plan for any future integration process.

EU and Ukraine flags
Ukraine has a long way to go before it potentially joins the EU, but the generics industry is already preparing for its ascension • Source: Shutterstock

Medicines for Europe has met with a high-level Ukrainian government delegation led by Maryna Slobodnichenko, the country’s deputy minister of health for European integration, putting forward ideas on how to plan the integration process of Ukraine into the EU.

Key takeaways:

  • The off-patent industry is making preparations for Ukraine’s eventual ascension into the EU. Several steps will need to be taken to align the Ukrainian pharmaceutical industry with EU standards, particularly regarding Good Manufacturing Practice and falsified medicines, as well as digitization

Kyiv applied for EU membership in February 2022 following the Russian invasion and was granted candidate status four months later....

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Generics

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Nichi-Iko Warns Over Delays From Toyama Plant

Nichi-Iko says that remediation activities at its Toyama plant in the wake of a suspension over GMP violations mean that there may be delays to supply.

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.